Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30532037 | 1.00 | ALDH1A1 (0.43) | ALDH1A1FERMT2HDAC1HDAC3HDAC2 | |
| SCHEMBL3631150 | 0.83 | ALDH1A1 (0.42) | ALDH1A1FERMT2HDAC1HDAC3HDAC2 | |
| SCHEMBL17378353 | 0.79 | HDAC1 (0.37) | ALDH1A1HDAC1HDAC2APPLMNA | |
| SCHEMBL8255720 | 0.79 | HDAC1 (0.44) | ALDH1A1HDAC1HDAC3PRSS1 | |
| SCHEMBL31172321 | 0.79 | NCF1 (0.44) | ALDH1A1HDAC1 | |
| SCHEMBL17845272 | 0.79 | PTGER4 (0.49) | ALDH1A1HDAC1HDAC3HDAC2LMNA | |
| SCHEMBL31122067 | 0.79 | PTGER4 (0.49) | ALDH1A1HDAC1HDAC3HDAC2LMNA | |
| SCHEMBL7746058 | 0.79 | NCF1 (0.44) | ALDH1A1HDAC1 | |
| SCHEMBL29624972 | 0.78 | LMNA (0.53) | ALDH1A1HDAC1HDAC3HDAC2KEAP1 | |
| SCHEMBL20345719 | 0.78 | LMNA (0.53) | ALDH1A1HDAC1HDAC3HDAC2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| CN-112979631-A | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10995073-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| CN-107295799-B | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20210060186-A1 | 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | PARP11, PARG, PARP16 | ALDH1A1 1411/4885FERMT2 3934/4885HDAC1 555/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ALDH1A1 1483/4885FERMT2 4104/4885HDAC1 642/4885 |
| US-20210060186-A1 | 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME | NPM1, ABL1, FLI1 | ALDH1A1 1686/4885FERMT2 2111/4885HDAC1 36/4885 |
| US-10995073-B2 | PARG inhibitory compounds | PARG, PARP11, PARP16 | ALDH1A1 1483/4885FERMT2 4104/4885HDAC1 642/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | ALDH1A1 1411/4885FERMT2 3934/4885HDAC1 555/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ALDH1A1 1483/4885FERMT2 4104/4885HDAC1 642/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ALDH1A1 1483/4885FERMT2 4104/4885HDAC1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.